Homepage
CREATE Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable, off-the-shelf treatments for cancer, autoimmunity, and fibrosis

CREATE Medicines is a clinical-stage biotech whose mRNA-LNP CARs program T cells, NK cells, and myeloid cells in the body.
createmedicines.comCrawled Nov 2, 2026
CREATE Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable, off-the-shelf treatments for cancer, autoimmunity, and fibrosis
CREATE Medicines partners with WestGene Biopharma to advance its in vivo CAR (chimeric antigen receptor) pipeline and lipid nanoparticle (LNP) delivery technology. The collaboration combines CREATE’s clinical-stage immune programming expertise with WestGene’s targeted LNP platforms and mRNA therapeutics. The agreement supports joint research and development to enhance therapeutic delivery systems for next-generation treatments.
CREATE Medicines is partnering with Monash University to advance its in vivo CAR (chimeric antigen receptor) platform. The collaboration includes an exclusive license agreement aimed at expanding targeted immune programming therapies. CREATE specializes in clinical-stage biotechnology solutions for in vivo immune programming.
CREATE Medicines secures $122 million in Series B funding to advance its in vivo CAR-T therapy pipeline targeting autoimmune diseases and oncology. The investment reflects rising investor focus on next-generation cell therapy solutions.
CREATE Medicines secures $122 million in Series B funding to advance its in vivo CAR-T cell therapy platform. The clinical-stage biotech firm aims to leverage the capital to accelerate pipeline development and expand research into next-generation immunotherapies. The investment underscores growing interest in in vivo approaches for cancer treatment.
CREATE Medicines secures $122 million in Series B funding to develop its in vivo CAR (chimeric antigen receptor) therapies for autoimmune diseases and oncology. The round includes participation from existing investors like Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, alongside new contributions from Alexandria Venture Investments. The company focuses on pioneering immune programming approaches to treat these conditions.